Transforming protein RhoA
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count | Chain A； UniProt 1–184 | Not recorded | Rho guanine nucleotide exchange factor 2 × 1 （Q92974） DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 15 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；2.6 M sodium formate, 100 mM Tris | Resolution 1.40 Å R-free 0.175 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 8BNT | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1A2B HUMAN RHOA COMPLEXED WITH GTP ANALOGUE Deposited 1997-12-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
Fragment：RESIDUES 1 - 181
|
Mutation：G14V, RESIDUES 1 - 181 WERE CLONED, THE N-TERMINUS CONTAINS A HIS-TAG | MG MAGNESIUM ION × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；CRYSTALS WERE OBTAINED AT 277 K BY THE HANGING-DROP VAPOR DIFFUSION METHOD FROM SOLUTIONS CONTAINING 10 MG/ML(PROTEIN,GTPGAMMAS,MG2+ MIXTURE), 10% PEG 8000,7.5% 14-DIOXANE, 50 MM TRIS-HCL PH 8.5, EQUILIBRATED AGAINST 20% PEG 8000,15% 14-DIOXANE, 100 MM TRIS-HCL PH 8.5, vapor diffusion - hanging drop
|
Resolution 2.40 Å R-free 0.268 |
| 1CC0 CRYSTAL STRUCTURE OF THE RHOA.GDP-RHOGDI COMPLEX Deposited 1999-03-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–190（190 aa）
|
Not recorded | MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.3；293 K；CRYSTALS GROWN BY VAPOR DIFFUSION IN A SITTING DROP USING EQUAL VOLUMES OF PROTEIN AND RESERVOIR. CRYSTALLIZATION OCCURED OVER A PERIOD OF SEVERAL DAYS AT 20 DEGREE CELSIUS. PROTEIN (15 MG/ML) WAS IN 25MM TRIS-HCL, PH=8.0, 100MM NACL, 5MM MGCL2. RESERVOIR CONTAINED: 51% SATURATED AMMONIUM SULFATE, 100 MM SODIUM ACETATE, PH=5.3, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 5.00 Å |
| 1CC0 CRYSTAL STRUCTURE OF THE RHOA.GDP-RHOGDI COMPLEX Deposited 1999-03-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
1–190（190 aa）
|
Not recorded | MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.3；293 K；CRYSTALS GROWN BY VAPOR DIFFUSION IN A SITTING DROP USING EQUAL VOLUMES OF PROTEIN AND RESERVOIR. CRYSTALLIZATION OCCURED OVER A PERIOD OF SEVERAL DAYS AT 20 DEGREE CELSIUS. PROTEIN (15 MG/ML) WAS IN 25MM TRIS-HCL, PH=8.0, 100MM NACL, 5MM MGCL2. RESERVOIR CONTAINED: 51% SATURATED AMMONIUM SULFATE, 100 MM SODIUM ACETATE, PH=5.3, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 5.00 Å |
| 1CXZ CRYSTAL STRUCTURE OF HUMAN RHOA COMPLEXED WITH THE EFFECTOR DOMAIN OF THE PROTEIN KINASE PKN/PRK1 Deposited 1999-08-31 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–181（181 aa）
Fragment：RESIDUES 1 - 181
|
Mutation：G14V | MG MAGNESIUM ION × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；pH 6.5；277 K；PEG 300, pH 6.5, MICROBATCH, temperature 277K
|
Resolution 2.20 Å R-free 0.268 |
| 1DPF CRYSTAL STRUCTURE OF A MG-FREE FORM OF RHOA COMPLEXED WITH GDP Deposited 1999-12-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–180（180 aa）
|
Mutation：G14V | GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；PEG400, citrate, Lithium sulfate,
magnesium chloride,, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.00 Å R-free 0.252 |
| 1FTN CRYSTAL STRUCTURE OF THE HUMAN RHOA/GDP COMPLEX Deposited 1997-03-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–193（193 aa）
|
Mutation：F25N | MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.10 Å R-free 0.304 |
| 1KMQ Crystal Structure of a Constitutively Activated RhoA Mutant (Q63L) Deposited 2001-12-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
4–181（178 aa）
|
Mutation：Q63L, F25N | MG MAGNESIUM ION × 2 GNP PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER × 1 DIO 1,4-DIETHYLENE DIOXIDE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.9；282 K；PEG 8000, HEPES, dioxane, magnesium chloride, 2-mercaptoethanol, pH 6.9, VAPOR DIFFUSION, temperature 282K
|
Resolution 1.55 Å R-free 0.190 |
| 1LB1 Crystal Structure of the Dbl and Pleckstrin homology domains of Dbs in complex with RhoA Deposited 2002-04-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1–190（190 aa）
Fragment：residues 1-190
|
Mutation：C190S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.4；292 K；PEG 3350, lithium citrate, Inositol 1,4,5-trisphosphate, pH 8.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
Resolution 2.81 Å R-free 0.266 |
| 1LB1 Crystal Structure of the Dbl and Pleckstrin homology domains of Dbs in complex with RhoA Deposited 2002-04-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
1–190（190 aa）
Fragment：residues 1-190
|
Mutation：C190S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.4；292 K；PEG 3350, lithium citrate, Inositol 1,4,5-trisphosphate, pH 8.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
Resolution 2.81 Å R-free 0.266 |
| 1LB1 Crystal Structure of the Dbl and Pleckstrin homology domains of Dbs in complex with RhoA Deposited 2002-04-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
1–190（190 aa）
Fragment：residues 1-190
|
Mutation：C190S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.4；292 K；PEG 3350, lithium citrate, Inositol 1,4,5-trisphosphate, pH 8.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
Resolution 2.81 Å R-free 0.266 |
| 1LB1 Crystal Structure of the Dbl and Pleckstrin homology domains of Dbs in complex with RhoA Deposited 2002-04-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
1–190（190 aa）
Fragment：residues 1-190
|
Mutation：C190S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.4；292 K；PEG 3350, lithium citrate, Inositol 1,4,5-trisphosphate, pH 8.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
Resolution 2.81 Å R-free 0.266 |
| 1OW3 Crystal Structure of RhoA.GDP.MgF3-in Complex with RhoGAP Deposited 2003-03-28 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1–193（193 aa）
|
Not recorded | MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 MGF TRIFLUOROMAGNESATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；18% PEG2KMME, 100mM MES, 10mM MgCl2, 10mM NaF, 2mM deferoxamine, 114mM (NH4)2SO4, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.80 Å R-free 0.219 |
| 1S1C Crystal structure of the complex between the human RhoA and Rho-binding domain of human ROCKI Deposited 2004-01-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–181（181 aa）
Fragment：RhoA
Chain B
1–181（181 aa）
Fragment：RhoA
|
Not recorded | MG MAGNESIUM ION × 2 GNP PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7.5；293 K；TRIS, PEG 3350, isopropyl alcohol, pH 7.5, EVAPORATION, temperature 293K
|
Resolution 2.60 Å R-free 0.257 |
| 1TX4 RHO/RHOGAP/GDP(DOT)ALF4 COMPLEX Deposited 1997-07-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
3–179（177 aa）
|
Not recorded | MG MAGNESIUM ION × 1 ALF TETRAFLUOROALUMINATE ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6；PROTEIN WAS CRYSTALLIZED FROM 18% PEG 2000 MME 100MM MES PH6.0 10MM MGCL2, 3MM DTT, 3MM NAN3, 114MM AMMONIUM SULFATE 400UM PROTEIN COMPLEX WITH 1MM ALCL3 AND 10MM NAF.
|
Resolution 1.65 Å R-free 0.215 |
| 1X86 Crystal Structure of the DH/PH domains of Leukemia-associated RhoGEF in complex with RhoA Deposited 2004-08-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1–193（193 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；277 K；PEG8K, sodium phosphate, sodium chloride, EDTA, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.22 Å R-free 0.279 |
| 1X86 Crystal Structure of the DH/PH domains of Leukemia-associated RhoGEF in complex with RhoA Deposited 2004-08-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
1–193（193 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；277 K；PEG8K, sodium phosphate, sodium chloride, EDTA, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.22 Å R-free 0.279 |
| 1X86 Crystal Structure of the DH/PH domains of Leukemia-associated RhoGEF in complex with RhoA Deposited 2004-08-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
1–193（193 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；277 K；PEG8K, sodium phosphate, sodium chloride, EDTA, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.22 Å R-free 0.279 |
| 1X86 Crystal Structure of the DH/PH domains of Leukemia-associated RhoGEF in complex with RhoA Deposited 2004-08-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
1–193（193 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；277 K；PEG8K, sodium phosphate, sodium chloride, EDTA, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.22 Å R-free 0.279 |
| 1XCG Crystal Structure of Human RhoA in complex with DH/PH fragment of PDZRHOGEF Deposited 2004-09-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
3–180（178 aa）
Fragment：RhoA
|
Mutation：F25N | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.2；298 K；PEG, Hepes, pH 7.2, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.50 Å R-free 0.281 |
| 1XCG Crystal Structure of Human RhoA in complex with DH/PH fragment of PDZRHOGEF Deposited 2004-09-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
3–180（178 aa）
Fragment：RhoA
|
Mutation：F25N | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.2；298 K；PEG, Hepes, pH 7.2, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.50 Å R-free 0.281 |
| 2RGN Crystal Structure of p63RhoGEF complex with Galpha-q and RhoA Deposited 2007-10-04 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
1–193（193 aa）
|
Not recorded | ALF TETRAFLUOROALUMINATE ION × 1 MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；100 mM HEPES pH 6.5, 14.5% PEG 3350, 400 mM KCl. Drops were microseeded to obtain large crystals, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.50 Å R-free 0.299 |
| 2RGN Crystal Structure of p63RhoGEF complex with Galpha-q and RhoA Deposited 2007-10-04 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain F
1–193（193 aa）
|
Not recorded | ALF TETRAFLUOROALUMINATE ION × 1 MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；100 mM HEPES pH 6.5, 14.5% PEG 3350, 400 mM KCl. Drops were microseeded to obtain large crystals, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.50 Å R-free 0.299 |
| 3KZ1 Crystal Structure of the Complex of PDZ-RhoGEF DH/PH domains with GTP-gamma-S Activated RhoA Deposited 2009-12-07 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
1–181（181 aa）
Fragment：UNP residues 1-181
|
Not recorded | MG MAGNESIUM ION × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；14-16% PEG 10000, 0.1M ammonium acetate, 0.1M Bis-Tris, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.70 Å R-free 0.283 |
| 3KZ1 Crystal Structure of the Complex of PDZ-RhoGEF DH/PH domains with GTP-gamma-S Activated RhoA Deposited 2009-12-07 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
1–181（181 aa）
Fragment：UNP residues 1-181
|
Not recorded | MG MAGNESIUM ION × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；14-16% PEG 10000, 0.1M ammonium acetate, 0.1M Bis-Tris, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.70 Å R-free 0.283 |
| 3LW8 Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex A) Deposited 2010-02-23 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
2–181（180 aa）
Fragment：residues 2-181
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；20% (w/v) PEG 3350, pH 7.5, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.85 Å R-free 0.233 |
| 3LW8 Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex A) Deposited 2010-02-23 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
2–181（180 aa）
Fragment：residues 2-181
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；20% (w/v) PEG 3350, pH 7.5, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.85 Å R-free 0.233 |
| 3LW8 Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex A) Deposited 2010-02-23 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
2–181（180 aa）
Fragment：residues 2-181
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；20% (w/v) PEG 3350, pH 7.5, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.85 Å R-free 0.233 |
| 3LW8 Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex A) Deposited 2010-02-23 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
2–181（180 aa）
Fragment：residues 2-181
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；20% (w/v) PEG 3350, pH 7.5, vapor diffusion, hanging drop, temperature 277K
|
Resolution 1.85 Å R-free 0.233 |
| 3LWN Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex B) Deposited 2010-02-24 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
2–181（180 aa）
Fragment：residues 2-181
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；20% (w/v) PEG 3350; protein was treated with EDTA prior to crystallization, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.28 Å R-free 0.291 |
| 3LWN Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex B) Deposited 2010-02-24 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
2–181（180 aa）
Fragment：residues 2-181
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；20% (w/v) PEG 3350; protein was treated with EDTA prior to crystallization, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.28 Å R-free 0.291 |
| 3LXR Shigella IpgB2 in complex with human RhoA and GDP (complex C) Deposited 2010-02-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
2–181（180 aa）
Fragment：residues 2-181
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 SO4 SULFATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；20% (w/v) PEG 3350; post-crystallization treatment: EDTA, LiSO4, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.68 Å R-free 0.219 |
| 3MSX Crystal structure of RhoA.GDP.MgF3 in complex with GAP domain of ArhGAP20 Deposited 2010-04-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–180（180 aa）
|
Mutation：F25N | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 MGF TRIFLUOROMAGNESATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；Crystallization drop was 1:1 mixture of protein dissolved in 20 mM Tris, pH 8.5, 100 mM NaCl, 5 mM NaF, 5 mM MgCl2, 5mM 2-mercaptoethanol and 20 w/v% PEG 8000, 0.2 M NaCl, 0.17 M NH4Cl, 0.1 M phosphate citrate buffer. The crystallization reservoir was 20 w/v% PEG 8000, 0.2 M NaCl, 0.17 M NH4Cl, 0.1 M phosphate citrate buffer, vapor diffusion, sitting drop, temperature 293K
|
Resolution 1.65 Å R-free 0.219 |
| 3T06 Crystal Structure of the DH/PH fragment of PDZRHOGEF with N-terminal regulatory elements in complex with Human RhoA Deposited 2011-07-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
3–180（178 aa）
|
Mutation：F25N | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；0.15 M DL-malic acid, 20 % w/v PEG 3350, pH 7.0, vapor diffusion, sitting drop, temperature 298K
|
Resolution 2.84 Å R-free 0.257 |
| 3T06 Crystal Structure of the DH/PH fragment of PDZRHOGEF with N-terminal regulatory elements in complex with Human RhoA Deposited 2011-07-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
3–180（178 aa）
|
Mutation：F25N | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；0.15 M DL-malic acid, 20 % w/v PEG 3350, pH 7.0, vapor diffusion, sitting drop, temperature 298K
|
Resolution 2.84 Å R-free 0.257 |
| 4D0N AKAP13 (AKAP-Lbc) RhoGEF domain in complex with RhoA Deposited 2014-04-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
Fragment：RESIDUES 1-184
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 SO4 SULFATE ION × 5 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；0.2 M AMMONIUM SULPHATE, 0.1 M BIS-TRIS PH 5.5, 25% (W/V) PEG 3350
|
Resolution 2.10 Å R-free 0.239 |
| 4XH9 CRYSTAL STRUCTURE OF HUMAN RHOA IN COMPLEX WITH DH/PH FRAGMENT OF THE GUANINE NUCLEOTIDE EXCHANGE FACTOR NET1 Deposited 2015-01-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
2–180（179 aa）
Fragment：UNP residues 2-180
|
Mutation：F25N | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M bisTris propane pH7.5, 20% PEG3350, 0.2M Tripotassium phosphate
|
Resolution 2.00 Å R-free 0.217 |
| 4XH9 CRYSTAL STRUCTURE OF HUMAN RHOA IN COMPLEX WITH DH/PH FRAGMENT OF THE GUANINE NUCLEOTIDE EXCHANGE FACTOR NET1 Deposited 2015-01-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
2–180（179 aa）
Fragment：UNP residues 2-180
|
Mutation：F25N | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M bisTris propane pH7.5, 20% PEG3350, 0.2M Tripotassium phosphate
|
Resolution 2.00 Å R-free 0.217 |
| 4XOI Structure of hsAnillin bound with RhoA(Q63L) at 2.1 Angstroms resolution Deposited 2015-01-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–180（180 aa）
Fragment：UNP residues 1-180
|
Mutation：Q63L | GTP GUANOSINE-5'-TRIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；12% PEG 3,350, 3% PEG 10000, 0.2 M sodium malonate, 5 mM DTT
|
Resolution 2.09 Å R-free 0.206 |
| 4XOI Structure of hsAnillin bound with RhoA(Q63L) at 2.1 Angstroms resolution Deposited 2015-01-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
1–180（180 aa）
Fragment：UNP residues 1-180
|
Mutation：Q63L | GTP GUANOSINE-5'-TRIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；12% PEG 3,350, 3% PEG 10000, 0.2 M sodium malonate, 5 mM DTT
|
Resolution 2.09 Å R-free 0.206 |
| 4XSG The complex structure of C3cer exoenzyme and GTP bound RhoA (NADH-free state) Deposited 2015-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–179（179 aa）
Fragment：UNP residues 1-179
|
Mutation：F25N | GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；100 mM MES (pH 6.4), 20% PEG1500
|
Resolution 1.80 Å R-free 0.223 |
| 4XSH The complex structure of C3cer exoenzyme and GTP bound RhoA (NADH-bound state) Deposited 2015-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–179（179 aa）
Fragment：UNP residues 1-179
|
Mutation：F25N | GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1 NAI 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE × 1 EDO 1,2-ETHANEDIOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；100 mM MES (pH 6.4), 20% PEG1500
|
Resolution 2.50 Å R-free 0.254 |
| 5A0F Crystal structure of Yersinia Afp18-modified RhoA Deposited 2015-04-20 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
Fragment：RESIDUES 1-181
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 SO4 SULFATE ION × 1 NDG 2-acetamido-2-deoxy-alpha-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.1 M SODIUM ACETATE, PH 5 AND 1.5 M AMMONIUM SULFATE; SITTING-DROP VAPOR-DIFFUSION AT 293.15 K
|
Resolution 2.00 Å R-free 0.213 |
| 5BWM The complex structure of C3cer exoenzyme and GDP bound RhoA (NADH-bound state) Deposited 2015-06-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–179（179 aa）
Fragment：UNP residues 1-179
|
Mutation：F25N | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 NAI 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE × 1 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；100 mM MES (pH 6.4), 20% PEG1500
|
Resolution 2.50 Å R-free 0.246 |
| 5C2K Crystal structure of the fusion protein linked by RhoA and the GAP domain of MgcRacGAP Deposited 2015-06-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–193（193 aa）
Fragment：GAP domain, UNP residues 346-546
|
Mutation：S249D | MG MAGNESIUM ION × 1 AF3 ALUMINUM FLUORIDE × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；PEG3350, Bis-Tris
|
Resolution 1.42 Å R-free 0.206 |
| 5C4M RhoA GDP with novel switch II conformation Deposited 2015-06-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–193（193 aa）
|
Mutation：F25N | MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；24% (w/v) PEG 3350, 0.3 NaCl
|
Resolution 1.30 Å R-free 0.200 |
| 5EZ6 Crystallization and preliminary X-ray crystallographic analysis of a small GTPase RhoA Deposited 2015-11-26 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–181（181 aa）
Fragment：UNP RESIDUES 1-181
|
Not recorded | MG MAGNESIUM ION × 3 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium citrate dibasic, 20% w/v Polyethylene glycol 3350
|
Resolution 1.80 Å R-free 0.213 |
| 5FR1 Double acetylated RhoGDI-alpha in complex with RhoA-GDP Deposited 2015-12-15 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–193（193 aa）
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；4 M SODIUM FORMATE, 0.1 M SODIUM ACETATE PH 4.5
|
Resolution 2.75 Å R-free 0.256 |
| 5FR2 Farnesylated RhoA-GDP in complex with RhoGDI-alpha, lysine acetylated at K178 Deposited 2015-12-15 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–193（193 aa）
|
Not recorded | FAR FARNESYL × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 BGC beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
0.2 M LITHIUMSULFATE 0.1 M BIS-TRIS PH5.5 25% PEG3350 30% DEXTROSE
|
Resolution 3.35 Å R-free 0.258 |
| 5HPY Crystal Structure of RhoA.GDP.MgF3-in complex with human Myosin 9b RhoGAP domain Deposited 2016-01-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
3–181（179 aa）
Fragment：UNP residues 3-181
|
Mutation：F25N | MGF TRIFLUOROMAGNESATE × 1 MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；289 K；20% (w/v) PEG 3350, 0.2M sodium malonate pH 7.0.
|
Resolution 2.40 Å R-free 0.246 |
| 5HPY Crystal Structure of RhoA.GDP.MgF3-in complex with human Myosin 9b RhoGAP domain Deposited 2016-01-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
3–181（179 aa）
Fragment：UNP residues 3-181
|
Mutation：F25N | MGF TRIFLUOROMAGNESATE × 1 MG MAGNESIUM ION × 2 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；289 K；20% (w/v) PEG 3350, 0.2M sodium malonate pH 7.0.
|
Resolution 2.40 Å R-free 0.246 |
| 5IRC p190A GAP domain complex with RhoA Deposited 2016-03-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
2–181（180 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | CL CHLORIDE ION × 2 GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 MGF TRIFLUOROMAGNESATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；294 K；30% PEG 2000MME
150mM KCSN
100mM MES, pH 6.5
|
Resolution 1.72 Å R-free 0.213 |
| 5IRC p190A GAP domain complex with RhoA Deposited 2016-03-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
2–181（180 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | CL CHLORIDE ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 MGF TRIFLUOROMAGNESATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；294 K；30% PEG 2000MME
150mM KCSN
100mM MES, pH 6.5
|
Resolution 1.72 Å R-free 0.213 |
| 5IRC p190A GAP domain complex with RhoA Deposited 2016-03-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
2–181（180 aa）
Chain F
2–181（180 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | CL CHLORIDE ION × 3 GDP GUANOSINE-5'-DIPHOSPHATE × 2 MG MAGNESIUM ION × 2 MGF TRIFLUOROMAGNESATE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；294 K；30% PEG 2000MME
150mM KCSN
100mM MES, pH 6.5
|
Resolution 1.72 Å R-free 0.213 |
| 5JCP RhoGAP domain of ARAP3 in complex with RhoA in the transition state Deposited 2016-04-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
2–181（180 aa）
Fragment：UNP residues 906-1107,UNP residues 2-181
|
Mutation：F25N | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 ALF TETRAFLUOROALUMINATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；100 mM MES, 15%(v/v) PEG 550 MME, 4%(v/v) Acetone
|
Resolution 2.10 Å R-free 0.227 |
| 5JCP RhoGAP domain of ARAP3 in complex with RhoA in the transition state Deposited 2016-04-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
2–181（180 aa）
Fragment：UNP residues 906-1107,UNP residues 2-181
|
Mutation：F25N | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 ALF TETRAFLUOROALUMINATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；100 mM MES, 15%(v/v) PEG 550 MME, 4%(v/v) Acetone
|
Resolution 2.10 Å R-free 0.227 |
| 5JHG Crystal structure of the complex between the human RhoA and the DH/PH domain of human ARHGEF11 Deposited 2016-04-21 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1–181（181 aa）
Fragment：UNP residues 1-181
|
Not recorded | GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；293 K；2% v/v Tacsimate pH 5.0, 0.1M Sodium citrate tribasic dihydrate pH 5.6, 16% PEG 3350
|
Resolution 2.50 Å R-free 0.270 |
| 5JHG Crystal structure of the complex between the human RhoA and the DH/PH domain of human ARHGEF11 Deposited 2016-04-21 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
1–181（181 aa）
Fragment：UNP residues 1-181
|
Not recorded | GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；293 K；2% v/v Tacsimate pH 5.0, 0.1M Sodium citrate tribasic dihydrate pH 5.6, 16% PEG 3350
|
Resolution 2.50 Å R-free 0.270 |
| 5JHH Crystal structure of the ternary complex between the human RhoA, its inhibitor and the DH/PH domain of human ARHGEF11 Deposited 2016-04-21 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1–181（181 aa）
Fragment：UNP residues 1-181
|
Not recorded | GOL GLYCEROL × 2 RA0 3-{3-[ethyl(quinolin-2-yl)amino]phenyl}propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；293 K；2% v/v Tacsimate pH 5.0, 0.1M Sodium citrate tribasic dihydrate pH 5.6, 16% PEG 3350
|
Resolution 2.30 Å R-free 0.239 |
| 5JHH Crystal structure of the ternary complex between the human RhoA, its inhibitor and the DH/PH domain of human ARHGEF11 Deposited 2016-04-21 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
1–181（181 aa）
Fragment：UNP residues 1-181
|
Not recorded | GOL GLYCEROL × 1 RA0 3-{3-[ethyl(quinolin-2-yl)amino]phenyl}propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；293 K；2% v/v Tacsimate pH 5.0, 0.1M Sodium citrate tribasic dihydrate pH 5.6, 16% PEG 3350
|
Resolution 2.30 Å R-free 0.239 |
| 5M6X Crystal Structure of human RhoGAP mutated in its arginine finger (R85A) in complex with RhoA.GDP.MgF3- human Deposited 2016-10-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
2–193（192 aa）
|
Not recorded | MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 MGF TRIFLUOROMAGNESATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；293 K；100 mM Bis Tris
pH 5.5-6.5
20-25% (w/v) PEG3350
|
Resolution 2.40 Å R-free 0.272 |
| 5M6X Crystal Structure of human RhoGAP mutated in its arginine finger (R85A) in complex with RhoA.GDP.MgF3- human Deposited 2016-10-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain I
2–193（192 aa）
|
Not recorded | MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 MGF TRIFLUOROMAGNESATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；293 K；100 mM Bis Tris
pH 5.5-6.5
20-25% (w/v) PEG3350
|
Resolution 2.40 Å R-free 0.272 |
| 5M70 Crystal Structure of human RhoGAP mutated in its arginin finger (R85A) in complex with RhoA.GDP.AlF4- human Deposited 2016-10-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
2–193（192 aa）
|
Not recorded | MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 ALF TETRAFLUOROALUMINATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；293 K；100 mM Bis/Tris pH 5.8-6
PEG3350 23-26%
|
Resolution 2.20 Å R-free 0.277 |
| 5M70 Crystal Structure of human RhoGAP mutated in its arginin finger (R85A) in complex with RhoA.GDP.AlF4- human Deposited 2016-10-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain G
2–193（192 aa）
|
Not recorded | MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 ALF TETRAFLUOROALUMINATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；293 K；100 mM Bis/Tris pH 5.8-6
PEG3350 23-26%
|
Resolution 2.20 Å R-free 0.277 |
| 5ZHX Crystal structure of SmgGDS-558 and farnesylated RhoA complex Deposited 2018-03-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain e
1–193（193 aa）
|
Mutation：L193A | FAR FARNESYL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；283 K；0.2M Sodium malonate, 20% PEG 3350
|
Resolution 3.50 Å R-free 0.306 |
| 5ZHX Crystal structure of SmgGDS-558 and farnesylated RhoA complex Deposited 2018-03-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain f
1–193（193 aa）
|
Mutation：L193A | FAR FARNESYL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；283 K；0.2M Sodium malonate, 20% PEG 3350
|
Resolution 3.50 Å R-free 0.306 |
| 5ZHX Crystal structure of SmgGDS-558 and farnesylated RhoA complex Deposited 2018-03-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain g
1–193（193 aa）
|
Mutation：L193A | FAR FARNESYL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；283 K；0.2M Sodium malonate, 20% PEG 3350
|
Resolution 3.50 Å R-free 0.306 |
| 5ZHX Crystal structure of SmgGDS-558 and farnesylated RhoA complex Deposited 2018-03-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain h
1–193（193 aa）
|
Mutation：L193A | FAR FARNESYL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；283 K；0.2M Sodium malonate, 20% PEG 3350
|
Resolution 3.50 Å R-free 0.306 |
| 6BC0 A Complex between PH Domain of p190RhoGEF and Activated RhoA Bound to a GTP Analog Deposited 2017-10-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
1–181（181 aa）
|
Not recorded | MG MAGNESIUM ION × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20-24% PEG 3350, 100mM TrisCl, 200mM NaCl
|
Resolution 2.20 Å R-free 0.281 |
| 6BCA A Complex between PH Domain of LbcRhoGEF (AKAP-Lbc) and Activated RhoA Bound to a GTP Analog Deposited 2017-10-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
1–181（181 aa）
|
Not recorded | MG MAGNESIUM ION × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；24-26% PEG 3350, 100mM Bis-Tris, 200mM ammonium sulfate
|
Resolution 2.00 Å R-free 0.234 |
| 6BCA A Complex between PH Domain of LbcRhoGEF (AKAP-Lbc) and Activated RhoA Bound to a GTP Analog Deposited 2017-10-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
1–181（181 aa）
|
Not recorded | MG MAGNESIUM ION × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；24-26% PEG 3350, 100mM Bis-Tris, 200mM ammonium sulfate
|
Resolution 2.00 Å R-free 0.234 |
| 6BCB A Complex between PH Domain of p114RhoGEF and Activated RhoA Bound to a GTP Analog Deposited 2017-10-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
1–181（181 aa）
|
Not recorded | GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；22-24% PEG 3350, 100mM Bis-Tris, 200mM NaCl
|
Resolution 1.40 Å R-free 0.165 |
| 6KX2 Crystal structure of GDP bound RhoA protein Deposited 2019-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Mutation：C16V, C20S, C83V, C159T | GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；289 K；10 mg/mL mutant, 0.2M NaCl; 0.1M acetate Na (pH 4.5) and 1.26M ammonium sulfate
|
Resolution 1.45 Å R-free 0.210 |
| 6KX3 Crystal structure of RhoA protein with covalent inhibitor DC-Rhoin Deposited 2019-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Mutation：C16V, C20S, C83V, C159T | GDP GUANOSINE-5'-DIPHOSPHATE × 1 8ZO prop-2-enyl (3R)-1,1-bis(oxidanylidene)-2,3-dihydro-1-benzothiophene-3-carboxylate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；289 K；10 mg/mL mutant, 0.2M NaCl, 0.1M acetate Na (pH 4.5), 1.26M ammonium sulfate
|
Resolution 1.98 Å R-free 0.268 |
| 6R3V Crystal Structure of RhoA-GDP-Pi in Complex with RhoGAP Deposited 2019-03-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1–193（193 aa）
|
Mutation：YES [F25N] | PO4 PHOSPHATE ION × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 DTT 2,3-DIHYDROXY-1,4-DITHIOBUTANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Equal amounts of reservoir solution containing 18% PEG2000
MME, 100 mM MES, pH 6.0, 10 mM MgCl2, 3 mM DTT, 3 mM NaN3,
120 mM ammonium sulphate and stock solution of the RhoA/RhoGAP protein complex at 800 mM in 20 mM Tris.HCl, pH 7.4, with 2 mM AlCl3, 10 mM MgCl2, and 20 mM NaF.
|
Resolution 1.75 Å R-free 0.207 |
| 6V6M Crystal structure of an inactive state of GMPPNP-bound RhoA Deposited 2019-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Mutation：F25N | GNP PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER × 1 MG MAGNESIUM ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；277 K；20-24% PEG8K, 15% Dioxane, 0.1M Tris pH8.0
|
Resolution 1.39 Å R-free 0.236 |
| 6V6U Crystal structure of RhoA-GDP with novel Switch I conformation Deposited 2019-12-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
Fragment：C-terminal trancated at residue 181
|
Mutation：F25N | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；277 K；20-24% PEG8K, 15% Dioxane, 0.1M Tris pH8.0
|
Resolution 1.16 Å R-free 0.185 |
| 6V6V Crystal structure of oncogenic RhoA mutant G14V complexed with GDP Deposited 2019-12-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
Fragment：C-terminal trancated at residue 181
|
Mutation：G14V, F25N | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；277 K；20-24% PEG8K, 15% Dioxane, 0.1M Tris pH8.0
|
Resolution 1.40 Å R-free 0.223 |
| 7G80 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1041785508 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | K34 5-(1,3-thiazol-2-yl)-1H-1,2,4-triazole × 1 DMS DIMETHYL SULFOXIDE × 3 FMT FORMIC ACID × 13 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.67 Å R-free 0.230 |
| 7G81 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104474512 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | H04 1-(2-ethoxyphenyl)piperazine × 2 DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.51 Å R-free 0.216 |
| 7G82 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1079512010 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | UWS 6-methyl-2-[(3-methyl-1,2-oxazol-5-yl)methyl]pyridazin-3(2H)-one × 3 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 15 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.41 Å R-free 0.209 |
| 7G83 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z108545814 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | YX2 3-propanamido-1-benzofuran-2-carboxamide × 2 DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 14 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.31 Å R-free 0.205 |
| 7G84 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1102357527 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | YX6 N-[(3R)-6-oxopiperidin-3-yl]-1,3-thiazole-4-carboxamide × 1 DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.81 Å R-free 0.232 |
| 7G85 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z111529496 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | LXA ~{N}-(1~{H}-benzimidazol-2-ylmethyl)-2-methoxy-ethanamide × 2 DMS DIMETHYL SULFOXIDE × 6 FMT FORMIC ACID × 13 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.74 Å R-free 0.223 |
| 7G86 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1137725943 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | YXB N-[(1H-indol-4-yl)methyl]ethanamine × 3 DMS DIMETHYL SULFOXIDE × 6 FMT FORMIC ACID × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.70 Å R-free 0.229 |
| 7G87 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1148165337 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | YG5 2-(1H-indazol-1-yl)-N,N-dimethylacetamide × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 14 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.05 Å R-free 0.241 |
| 7G88 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1148747945 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | WKY N-(3-methylpyridin-4-yl)acetamide × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.87 Å R-free 0.244 |
| 7G89 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1192341021 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | ZT7 1-(5-amino-2H-isoindol-2-yl)ethan-1-one × 2 DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 9 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.90 Å R-free 0.244 |
| 7G8A ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z100642432 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | WJ7 2-bromo-4-fluoro-N,N-dimethylbenzamide × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 15 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.50 Å R-free 0.211 |
| 7G8B ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z100643660 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | LFO N,1-dimethyl-1H-indole-3-carboxamide × 4 DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 14 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.42 Å R-free 0.216 |
| 7G8C ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1037511924 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | YXO 1-(difluoromethyl)-1H-indol-5-amine × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.18 Å R-free 0.255 |
| 7G8D ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104474228 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 12 60P 3-methylthiophene-2-carboxylic acid × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.94 Å R-free 0.236 |
| 7G8E ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104479710 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 12 YXH 1-(1H-benzimidazol-2-yl)methanamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.79 Å R-free 0.223 |
| 7G8F ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1079168976 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | YXK [1-(2,2,2-trifluoroethyl)-1H-imidazol-2-yl]acetonitrile × 1 DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.42 Å R-free 0.215 |
| 7G8G ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z111529496 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | LXA ~{N}-(1~{H}-benzimidazol-2-ylmethyl)-2-methoxy-ethanamide × 2 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.92 Å R-free 0.251 |
| 7G8H ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1198180782 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | YXU 5-methoxy-1H-pyrrolo[3,2-b]pyridine × 3 DMS DIMETHYL SULFOXIDE × 8 FMT FORMIC ACID × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.67 Å R-free 0.218 |
| 7G8I ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1198316457 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | YXY 4,4-difluorocyclohexane-1-carboxamide × 1 DMS DIMETHYL SULFOXIDE × 3 FMT FORMIC ACID × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.47 Å R-free 0.273 |
| 7G8J ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1216861874 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | YYI 5-(difluoromethoxy)pyridin-2(3H)-one × 1 DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.99 Å R-free 0.281 |
| 7G8K ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1217131798 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | YZK (3M)-3-(2-methyl-1H-imidazol-1-yl)pyridine × 3 DMS DIMETHYL SULFOXIDE × 6 FMT FORMIC ACID × 14 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.49 Å R-free 0.216 |
| 7G8L ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1251207602 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | RWS 1-(5-methyl-1,3,4-thiadiazol-2-yl)piperidine × 4 DMS DIMETHYL SULFOXIDE × 6 FMT FORMIC ACID × 13 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.60 Å R-free 0.229 |
| 7G8M ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1255459547 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | Z0I N-(1H-indol-7-yl)acetamide × 1 DMS DIMETHYL SULFOXIDE × 3 FMT FORMIC ACID × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.03 Å R-free 0.260 |
| 7G8N ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1262549981 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | Z1L 1-anilinocyclopropane-1-carboxylic acid × 1 DMS DIMETHYL SULFOXIDE × 3 FMT FORMIC ACID × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.32 Å R-free 0.283 |
| 7G8O ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1267800292 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | O2A N-methyl-1H-indole-7-carboxamide × 3 DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.58 Å R-free 0.230 |
| 7G8P ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1269184613 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | Z2F 1,3-benzothiazole-6-sulfonamide × 1 DMS DIMETHYL SULFOXIDE × 3 FMT FORMIC ACID × 7 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.21 Å R-free 0.324 |
| 7G8Q ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1269220427 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | Z2Z 8-(methanesulfonyl)quinoline × 2 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 13 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.56 Å R-free 0.207 |
| 7G8R ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1270087714 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | Z5Z (2R,6S)-2,6-dimethyl-4-(3-methyl-1,2,4-thiadiazol-5-yl)morpholine × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 13 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.44 Å R-free 0.207 |
| 7G8S ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1270393711 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | Z5C 5-(methoxymethyl)-1,2-oxazole-3-carboxamide × 3 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 13 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.60 Å R-free 0.222 |
| 7G8T ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1273312142 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 14 Z4X 2-ethoxy-3-fluoro-N,N-dimethylbenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.39 Å R-free 0.198 |
| 7G8U ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z131833926 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 3 FMT FORMIC ACID × 6 Z3O (3S)-3-{[(4R)-4-methyl-3,4-dihydropyridin-1(2H)-yl]methyl}-3H-indole × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.44 Å R-free 0.294 |
| 7G8V ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z133716556 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | Z3H N-[(4R)-3,4-dihydro-2H-1-benzopyran-4-yl]methanesulfonamide × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 14 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.45 Å R-free 0.219 |
| 7G8W ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1416193393 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | Z6I 4-(5-methyl-1H-pyrazol-4-yl)piperidine × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 13 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.94 Å R-free 0.250 |
| 7G8X ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1416571195 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | Z7T 2-(cyclopentylamino)pyridine-4-carboxamide × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.71 Å R-free 0.227 |
| 7G8Y ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1449748885 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | WZY N-(4-methoxyphenyl)glycinamide × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 14 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.75 Å R-free 0.222 |
| 7G8Z ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1493056027 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 7 FMT FORMIC ACID × 14 Z9I 1-[(2R)-1-(methanesulfonyl)pyrrolidin-2-yl]methanamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.51 Å R-free 0.221 |
| 7G90 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1509195674 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | ZA9 4-[(3S)-piperidin-3-yl]-1H-indole × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.91 Å R-free 0.249 |
| 7G91 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1509257513 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | ZBH (4S)-N,2-dimethyl-4,5,6,7-tetrahydro-1,3-benzothiazole-4-carboxamide × 1 DMS DIMETHYL SULFOXIDE × 3 FMT FORMIC ACID × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.29 Å R-free 0.253 |
| 7G92 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1545313172 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | LWA (2~{S})-~{N}-(4-aminocarbonylphenyl)oxolane-2-carboxamide × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 14 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.87 Å R-free 0.237 |
| 7G93 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1565771450 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | VW7 N-(8-methyl-1,2,3,4-tetrahydroquinolin-5-yl)acetamide × 2 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.69 Å R-free 0.225 |
| 7G94 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1575337975 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | ZC9 (2P)-5-fluoro-2-(1H-pyrazol-5-yl)pyridine × 3 DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 13 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.47 Å R-free 0.224 |
| 7G95 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z165170770 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | W0Y N-methyl-4-sulfamoylbenzamide × 4 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.55 Å R-free 0.218 |
| 7G96 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1203730981 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | ZCI 2-bromo-1H-imidazole × 2 DMS DIMETHYL SULFOXIDE × 3 FMT FORMIC ACID × 9 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.30 Å R-free 0.266 |
| 7G97 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z57899718 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | APY 2-AMINOMETHYL-PYRIDINE × 1 DMS DIMETHYL SULFOXIDE × 3 FMT FORMIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.30 Å R-free 0.249 |
| 7G98 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z4605084898 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 2 FMT FORMIC ACID × 4 ZDL 1,3-dimethylimidazolidine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.88 Å R-free 0.295 |
| 7G99 ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102102-001 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | ZE9 1-[(3R,5R)-5-(furan-2-yl)-3-(5-methylfuran-2-yl)pyrazolidin-1-yl]ethan-1-one × 2 DMS DIMETHYL SULFOXIDE × 6 FMT FORMIC ACID × 13 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.78 Å R-free 0.237 |
| 7G9A ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102113-001 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 2 FMT FORMIC ACID × 11 ZEK 3-acetamido-N-methylbenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.58 Å R-free 0.295 |
| 7G9B ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102116-001 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 2 FMT FORMIC ACID × 7 ZG0 N-(3-methylphenyl)acetamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.55 Å R-free 0.298 |
| 7G9C ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102141-001 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 8 ZFI N-[2-(methanesulfonyl)phenyl]acetamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.69 Å R-free 0.274 |
| 7G9D ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102179-001 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 2 FMT FORMIC ACID × 9 T7Y N-[3-(2-oxopyrrolidin-1-yl)phenyl]acetamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.66 Å R-free 0.286 |
| 7G9E ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102197-001 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 10 ZG6 N-(3-methyl-1,2-oxazol-5-yl)acetamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.15 Å R-free 0.292 |
| 7G9F ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102209-001 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 10 ZGF N-(6-chloro-2H-1,3-benzodioxol-5-yl)acetamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.94 Å R-free 0.260 |
| 7G9G ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102236-001 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 3 FMT FORMIC ACID × 11 ZGK N-(2-methoxyphenyl)acetamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.08 Å R-free 0.286 |
| 7G9H ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102245-001 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 2 FMT FORMIC ACID × 7 KLU (2S)-4-(chloroacetyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.75 Å R-free 0.274 |
| 7G9I ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102253-001 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | ZGQ N-[(2-methylphenyl)methyl]acetamide × 1 DMS DIMETHYL SULFOXIDE × 4 FMT FORMIC ACID × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 2.20 Å R-free 0.274 |
| 7G9J ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102281-001 Deposited 2023-06-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–184（184 aa）
|
Not recorded | ZGX 1-(3,4-dihydropyrazin-1(2H)-yl)ethan-1-one × 1 DMS DIMETHYL SULFOXIDE × 5 FMT FORMIC ACID × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 2.6M sodium formate
|
Resolution 1.97 Å R-free 0.245 |
| 7QSC GTPase IN COMPLEX WITH GDP.MGF3- Deposited 2022-01-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
2–193（192 aa）
Chain D
2–193（192 aa）
|
Mutation：Y34(F3Y) Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Y34(F3Y) Non-standard monomer：Yes (specific site not provided by mmCIF) | GDP GUANOSINE-5'-DIPHOSPHATE × 2 MGF TRIFLUOROMAGNESATE × 2 MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；Protein stock of RhoA-Y34F3Y 0.7 mM, RhoGAP-R85A 0.7 mM in a buffer of BisTris-HCl, pH 6.0, NaCl 150 mM, MgCl2 5 mM, NaF 10 mM, DTT 1 mM mixed 1:1.2 ratio with the
precipitant solution of 0.1 M BisTris-HCl, pH 5.8, PEG3350 26% (w/v).
|
Resolution 1.91 Å R-free 0.294 |
| 7QTM Transition state analogue of small G protein in complex with relevant GAP Deposited 2022-01-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
2–193（192 aa）
Chain I
2–193（192 aa）
|
Mutation：Y34(F2Y) Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Y34(F2Y) Non-standard monomer：Yes (specific site not provided by mmCIF) | GDP GUANOSINE-5'-DIPHOSPHATE × 2 MGF TRIFLUOROMAGNESATE × 2 MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；A 1:1 ratio of protein buffer (RhoA 0.7 mM, RhoGAP-R85A 0.7 M, BisTris-HCl pH = 6.0, NaCl 150 mM, MgCl2 5 mM, NaF 10 mM, DTT 1 mM) to precipitant (0.1 M BisTris-HCl pH = 5.8, PEG3350 25% (w/v)) was used
|
Resolution 2.25 Å R-free 0.304 |
| 7WZA An open conformation Form 1 of switch II for RhoA Deposited 2022-02-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Mutation：C16V,C20S,C83V,C159T | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；20% PEG 3350, 0.2M potassium formate
|
Resolution 1.50 Å R-free 0.220 |
| 7WZC An open conformation Form2 of switch II for RhoA GDP-bound state Deposited 2022-02-17 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
Fragment：C16V,C20S,C83V,C159T
|
Not recorded | GOL GLYCEROL × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；0.1M MES, pH6.0, 30% PEG 600, 5% PEG 1000, 10% glycerol
|
Resolution 1.80 Å R-free 0.264 |
| 8FC7 Cryo-EM structure of the human TRPV4 - RhoA in complex with GSK2798745 Deposited 2022-12-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain E
1–193（193 aa）
Chain F
1–193（193 aa）
Chain G
1–193（193 aa）
Chain H
1–193（193 aa）
|
Not recorded | XPW 1-({(5S,7S)-3-[5-(2-hydroxypropan-2-yl)pyrazin-2-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl}methyl)-1H-benzimidazole-6-carbonitrile × 4 MG MAGNESIUM ION × 4 GDP GUANOSINE-5'-DIPHOSPHATE × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 8FC9 Cryo-EM structure of the human TRPV4 - RhoA, apo condition Deposited 2022-12-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain E
1–193（193 aa）
Chain F
1–193（193 aa）
Chain G
1–193（193 aa）
Chain H
1–193（193 aa）
|
Not recorded | MG MAGNESIUM ION × 4 GDP GUANOSINE-5'-DIPHOSPHATE × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.75 Å |
| 8FCB Cryo-EM structure of the human TRPV4 - RhoA in complex with GSK1016790A Deposited 2022-12-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain E
1–193（193 aa）
Chain F
1–193（193 aa）
Chain G
1–193（193 aa）
Chain H
1–193（193 aa）
|
Not recorded | XQ3 N-[(2S)-1-{4-[N-(2,4-dichlorobenzene-1-sulfonyl)-L-seryl]piperazin-1-yl}-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide × 4 Y01 CHOLESTEROL HEMISUCCINATE × 4 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.52 Å |
| 8FPW Crystal structure of tumor related RhoA mutant A161V in complex with GDP Deposited 2023-01-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Mutation：F25N, A161V | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；20-24% PEG8K, 15% Dioxane, 0.1M Tris pH8.0
|
Resolution 1.40 Å R-free 0.208 |
| 8FPX Crystal structure of tumor related RhoA mutant A161P in complex with GDP Deposited 2023-01-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Mutation：F25N, A161P | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；20-24% PEG8K, 15% Dioxane, 0.1M Tris pH8.0
|
Resolution 1.47 Å R-free 0.225 |
| 8GI3 Crystal structure of RhoA mutant L69P complexed with GDP Deposited 2023-03-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–193（193 aa）
|
Mutation：L69P | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；pH 5.1；293.2 K；0.2 M Ammonium citrate dibasic (pH 5.1), 20% PEG3350
|
Resolution 1.52 Å R-free 0.209 |
| 8GI6 Crystal structure of RhoA mutant L69R complexed with GDP Deposited 2023-03-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–193（193 aa）
|
Mutation：L69R | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；pH 5.7；293.15 K；0.1 M Na acetate (pH 5.7), 0.5 mM Na citrate, 26% PEG4000, 5% glycerol
|
Resolution 1.40 Å R-free 0.182 |
| 8JVJ Structure of human TRPV4 with antagonist A2 and RhoA Deposited 2023-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain E
1–193（193 aa）
Chain F
1–193（193 aa）
Chain G
1–193（193 aa）
Chain H
1–193（193 aa）
|
Not recorded | F9M [6-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)-1,3-thiazol-2-yl]amino]pyridin-3-yl]-[(1~{S},5~{R})-3-[5-(trifluoromethyl)pyrimidin-2-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.44 Å |
| 8T1C Cryo-EM structure of human TRPV4 ankyrin repeat domain in complex with GTPase RhoA Deposited 2023-06-02 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
1–193（193 aa）
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.49 Å |
| 8ZNY Small GTPase RhoA Y42C mutant in complex with GDP Deposited 2024-05-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Mutation：Y42C | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289.15 K；0.2 M Ammonium acetate, o.1 M Sodium acetate trihydrate (pH 4.6), 30% PEG4000
|
Resolution 1.65 Å R-free 0.217 |
| 8ZO0 Samll GTPase RhoA Y42C mutant in complex with GTP analogue Deposited 2024-05-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Mutation：Y42C | GNP PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289.15 K；0.1 M Bis-Tris (pH 5.5), 25% PEG3350
|
Resolution 2.21 Å R-free 0.240 |
| 9AX5 Cryo-EM structure of Phospholipase C epsilon PH-C terminus in complex with RhoA-GTP Deposited 2024-03-05 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
2–193（192 aa）
|
Not recorded | CA CALCIUM ION × 1 GTP GUANOSINE-5'-TRIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 9IQX Cryo-EM structure of the human TRPV4-RhoA in complex with AH001 Deposited 2024-07-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain E
1–193（193 aa）
Chain F
1–193（193 aa）
|
Not recorded | P5S O-[(R)-{[(2R)-2,3-bis(octadecanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine × 2 U6L (1~{R})-1-(3-ethylphenyl)ethane-1,2-diol × 2 GDP GUANOSINE-5'-DIPHOSPHATE × 2 MG MAGNESIUM ION × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.37 Å |
| 9IQY Cryo-EM structure of human TRPV4 intracellular domain in complex with GTPase RhoA Deposited 2024-07-13 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain J
1–193（193 aa）
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.16 Å |
| 9J0G Crystal structure of RhoA-TP1001 complex Deposited 2024-08-02 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–193（193 aa）
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；289 K；0.5 M Lithium sulfate monohydrate,0.1 M HEPES pH 7.5,30% w/v Polyethylene glycol 3,350
|
Resolution 3.10 Å R-free 0.354 |
| 9J0G Crystal structure of RhoA-TP1001 complex Deposited 2024-08-02 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–193（193 aa）
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；289 K；0.5 M Lithium sulfate monohydrate,0.1 M HEPES pH 7.5,30% w/v Polyethylene glycol 3,350
|
Resolution 3.10 Å R-free 0.354 |
| 9J0G Crystal structure of RhoA-TP1001 complex Deposited 2024-08-02 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
1–193（193 aa）
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；289 K；0.5 M Lithium sulfate monohydrate,0.1 M HEPES pH 7.5,30% w/v Polyethylene glycol 3,350
|
Resolution 3.10 Å R-free 0.354 |
| 9J0G Crystal structure of RhoA-TP1001 complex Deposited 2024-08-02 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
1–193（193 aa）
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 2 U6L (1~{R})-1-(3-ethylphenyl)ethane-1,2-diol × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；289 K；0.5 M Lithium sulfate monohydrate,0.1 M HEPES pH 7.5,30% w/v Polyethylene glycol 3,350
|
Resolution 3.10 Å R-free 0.354 |
| 9N4A Wild-type RhoA GTPase bound to GppNHp Deposited 2025-02-02 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Not recorded | DIO 1,4-DIETHYLENE DIOXIDE × 1 MG MAGNESIUM ION × 2 GNP PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291.18 K；2 uL protein (10 mg/mL RhoA-GppNHp, 25 mM Tris-HCl pH 8.0, 2 mM MgCl2, 10 mM BME) + 2 uL of crystallization solution over 500 uL reservoir of crystallization solution. Crystallization solution: 25% dioxane, 17% PEG 8000, and 100 mM HEPES pH 6.9
|
Resolution 1.95 Å R-free 0.221 |
| 9N4A Wild-type RhoA GTPase bound to GppNHp Deposited 2025-02-02 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–181（181 aa）
|
Not recorded | DIO 1,4-DIETHYLENE DIOXIDE × 1 MG MAGNESIUM ION × 2 GNP PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291.18 K；2 uL protein (10 mg/mL RhoA-GppNHp, 25 mM Tris-HCl pH 8.0, 2 mM MgCl2, 10 mM BME) + 2 uL of crystallization solution over 500 uL reservoir of crystallization solution. Crystallization solution: 25% dioxane, 17% PEG 8000, and 100 mM HEPES pH 6.9
|
Resolution 1.95 Å R-free 0.221 |
| 9N4B RhoA GTPase R70A bound to GTPgammaS Deposited 2025-02-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
3–181（179 aa）
|
Mutation：R70A | MG MAGNESIUM ION × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277.15 K；2 uL protein (8 mg/mL RhoA R70A bound to GTPgammaS in 25 mM Tris-HCl pH8.0, 2 mM MgCl2, and 10 mM BME) + 2 uL crystallization reagent sitting above 500 uL crystallization reagent. Crystallization reagent: 250 mM ammonium sulfate, 1.50 M lithium sulfate, and 100 mM sodium citrate pH 5.6
|
Resolution 3.00 Å R-free 0.247 |
| 9N4C RhoA GTPase E102A bound to GTPgammaS Deposited 2025-02-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Mutation：E102A | GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1 IOD IODIDE ION × 5 CL CHLORIDE ION × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；2 uL protein (8 mg/mL RhoA E102A bound to GTPgammaS, 25 mM Tris-HCl pH 8.0, 2 mM MgCl2, 10 mM BME) + 2 uL of crystallization solution over 500 uL reservoir of crystallization solution. Crystallization solution: 0.2 M Ammonium iodide, 20% PEG 3,350
|
Resolution 2.30 Å R-free 0.220 |
| 9N4C RhoA GTPase E102A bound to GTPgammaS Deposited 2025-02-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–181（181 aa）
|
Mutation：E102A | GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1 IOD IODIDE ION × 8 CL CHLORIDE ION × 9 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；2 uL protein (8 mg/mL RhoA E102A bound to GTPgammaS, 25 mM Tris-HCl pH 8.0, 2 mM MgCl2, 10 mM BME) + 2 uL of crystallization solution over 500 uL reservoir of crystallization solution. Crystallization solution: 0.2 M Ammonium iodide, 20% PEG 3,350
|
Resolution 2.30 Å R-free 0.220 |
| 9N4C RhoA GTPase E102A bound to GTPgammaS Deposited 2025-02-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
1–181（181 aa）
|
Mutation：E102A | GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 2 IOD IODIDE ION × 5 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；2 uL protein (8 mg/mL RhoA E102A bound to GTPgammaS, 25 mM Tris-HCl pH 8.0, 2 mM MgCl2, 10 mM BME) + 2 uL of crystallization solution over 500 uL reservoir of crystallization solution. Crystallization solution: 0.2 M Ammonium iodide, 20% PEG 3,350
|
Resolution 2.30 Å R-free 0.220 |
| 9N4C RhoA GTPase E102A bound to GTPgammaS Deposited 2025-02-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
1–181（181 aa）
|
Mutation：E102A | GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1 IOD IODIDE ION × 12 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；2 uL protein (8 mg/mL RhoA E102A bound to GTPgammaS, 25 mM Tris-HCl pH 8.0, 2 mM MgCl2, 10 mM BME) + 2 uL of crystallization solution over 500 uL reservoir of crystallization solution. Crystallization solution: 0.2 M Ammonium iodide, 20% PEG 3,350
|
Resolution 2.30 Å R-free 0.220 |
| 9VNG Small GTPase RhoA Y42C mutant in complex with covalent inhibitor Deposited 2025-06-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Mutation：Y42C | GDP GUANOSINE-5'-DIPHOSPHATE × 1 A1D9L 4-(2-nitroethyl)-1~{H}-indole × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；289.15 K；0.2 M Ammonium acetate, 0.1 M Sodium acetate trihydrate pH 4.6, 30% w/v Polyethylene glycol 4000
|
Resolution 1.43 Å R-free 0.221 |
| 9VNH Structure of wild-type RhoA in complex with GDP and magnesium ion Deposited 2025-06-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Not recorded | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；289.15 K；0.2 M Ammonium chloride, 0.01 M Calcium chloride dihydrate, 0.05 M TRIS hydrochloride pH 8.5, 30% w/v Polyethylene glycol 4000
|
Resolution 1.79 Å R-free 0.231 |
| 9VNI Structure of the RhoA Y42C mutant featuring Thr37 coordination of magnesium ion Deposited 2025-06-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–181（181 aa）
|
Mutation：Y42C | GDP GUANOSINE-5'-DIPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289.15 K；10% v/v 2-Propanol, 0.1 M Sodium acetate trihydrate pH 4.0, 22% w/v Polyethylene glycol 6000
|
Resolution 1.83 Å R-free 0.247 |
129 other PDB entries and 165 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | RHOA_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 2–185； UniProt 1–184 |
